US FDA's Patient Experience Data Guidance Calls More Attention To Burdens Of Surveys

 
• By Sue Sutter
  
Focus lens
An FDA PFDD final guidance puts more focus on the accessibility and burden of quantitative data collection for patients. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from R&D

More from Pink Sheet